Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. [electronic resource]
Producer: 20070327Description: 675-81 p. digitalISSN:- 1527-7755
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Bridged-Ring Compounds -- adverse effects
- Disease Progression
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Orchiectomy
- Probability
- Prognosis
- Prostatic Neoplasms -- drug therapy
- Receptor, ErbB-2 -- administration & dosage
- Risk Assessment
- Single-Blind Method
- Survival Analysis
- Taxoids -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.